RET-IN-13

Cat. No.:	HY-144029
CAS No.:	2684258-54-4
Molecular Formula:	$C_{32}H_{33}F_4N_5O_3$
Molecular Weight:	611.63
Target:	RET
Pathway:	Protein Tyrosine Kinase/RTK
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	RET-IN-13 (compound 1), a quinoline compound, is a potent RET inhibitor with IC_{50}s of 0.5 nM, 0.9 nM for RET (WT) and RET (V804M), respectively. RET-IN-13 has the potential for tumors or intestinal diseases related to abnormal activation of RET research[1].
In Vitro	RET-IN-13 has low inhibition on CYP1A2 (IC_{50}>50 μM), CYP2C9 (IC_{50}=12.5 μM), CYP2C19 (IC_{50}=16.9 μM), CYP2D6 (IC_{50}=18.8 μM) and CYP3A4 (IC_{50}>50 μM)[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	RET-IN-13 (compound 1; 0.5 mpk; iv) has a $T_{1/2}$ of 6.93 hours, a CL of 2.68 mL/min·kg, and a Vd_{ss} of 1.52 L/kg for male mice[1]. RET-IN-13 (2.5 mpk; po) has a $T_{1/2}$ of 5.16 hours, C_{max} of 0.958 μM and an AUC of 12477 μM·hr for male mice[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Jiansong Wang, et al. Quinoline compounds. WO2021164742A1.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA